<DOC>
	<DOCNO>NCT02768545</DOCNO>
	<brief_summary>NPC1L1 key transporter enterohepatic cycle cholesterol . Initial vitro vivo data show block receptor ezetimibe result delay infection model . The investigator hypothesize HCV enterohepatic cycle , secrete bile reabsorbed either canalicular membrane intestine association NPC1L1 , follow path similar cycle cholesterol human . To prove hypothesis investigator propose assess effect ezetimibe treatment HCV infect individual undergo liver transplantation avoid delay HCV infection . For purpose , investigator propose administrate ezetimibe 10 mg/d 12 week 12 patient chronic hepatitis C infection list liver transplantation .</brief_summary>
	<brief_title>Study Ezetimibe Chronic Hepatitis C Virus ( HCV ) Infection Liver Transplant Candidates ( EZE-2 )</brief_title>
	<detailed_description>Infection hepatitis C virus ( HCV ) affect 170 million people World 80.000 Chile . It cause deaths HIV infection US lead cause liver transplantation Chile . Even though treatment evolve new direct antiviral agent ( DAAs ) increase response rate , several issue new approach , include toxicity , need use interferon ribavirin , complex algorithm treatment , high cost , limited effectivity certain group ( liver transplant patient ) drug interaction . Treatments target host factor require viral cycle become increasingly explore alternative complement DAAs . HCV intimate connection host lipidic pathway , alter lipid profile , circulate bound lipoproteins use cholesterol receptor intracellular mechanism fat metabolism . It recently describe NPC1L1 ( Niemann-Pick C1-like 1 ) , intestinal receptor cholesterol , serve entry factor HCV . Interestingly , receptor express enterocytes ( absorb endogenous dietary cholesterol ) , also canalicular membrane hepatocyte , function absorb cholesterol secrete canalicular lumen . NPC1L1 , therefore , key transporter enterohepatic cycle cholesterol . Initial in-vitro in-vivo data show block receptor ezetimibe result delay infection model . Moreover , report case patient 3 unsuccessful treatment attempt , clear HCV RNA ezetimibe treatment , first report effect ezetimibe human . In view observation , investigator hypothesize HCV enterohepatic cycle , secrete bile reabsorbed either canalicular membrane intestine association NPC1L1 , follow path similar cycle cholesterol human . This possibility support observation HCV RNA detect bile feces infect human . To prove hypothesis , investigator propose assess effect ezetimibe treatment HCV-infected individual . Ezetimibe approve generally safe drug use management hypercholesterolemia . HCV RNA core antigen plasma feces assess . An increase bile fecal HCV load antagonize NPC1L1 ezetimibe support notion HCV reabsorb canalicular membrane intestinal level . The second part propose study conduct 12 patient chronic hepatitis C list liver transplantation . Graft reinfection liver transplant universal . Here investigator anticipate use ezetimibe directly impact reinfection time graft , delay even prevent liver reinfection patient . Should study successful sure enormous implication design novel management strategy liver transplant patient .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Chronic hepatitis C define detectable HCV RNA 6 month . Age &gt; 18 year old . No current HCV antiviral treatment . No medication dyslipidemia precede 2 month . Listed national wait list liver transplant estimate time transplantation 3 month less , either complication cirrhosis hepatocellular carcinoma . No abdominal surgery could alter biliary intestinal anatomy . HCV RNA level &gt; 10.000 IU/mL . No evidence sitosterolemia . Negative pregnancy test urine ( female ) . Signed informed consent document . Hepatitis B HIV coinfection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Enterohepatic Circulation</keyword>
	<keyword>Bile</keyword>
	<keyword>Feces</keyword>
</DOC>